Latest Commercial Partnerships News

Page 1 of 22
FortifAI has appointed former NVIDIA and Elastic sales leader Jason Brushe as CEO, putting commercial partnerships at the centre of NOL8’s next phase. His package includes US$300,000 in annual remuneration and performance rights tied to agreements, partnerships and bookings milestones.
Sophie Babbage
Sophie Babbage
19 Nov 2026
PhosCo’s updated scoping study gives its 100%-owned Gasaat phosphate project in Tunisia a US$732 million post-tax NPV, 52% IRR and 49-year mine life. The economics are substantial, but the project still needs a mining concession, water supply, offtake agreements and about US$220 million in funding.
Maxwell Dee
Maxwell Dee
9 Nov 2026
INOVIQ has secured a validation agreement with Sonic Healthcare USA for its EXO-OC ovarian cancer test, opening a potential route into the US laboratory-developed test market. The commercial opportunity remains conditional: Sonic has not committed to a licence, and validation is expected to run for 12 to 18 months.
Ada Torres
Ada Torres
2 Nov 2026
Algorae Pharmaceuticals has moved closer to its first expected NSW Health supply orders while reporting stronger preclinical results from its AOS2 drug-discovery platform. The company ended September with $3.15 million in cash and a further $3 million undrawn facility, but its commercial contract carries no minimum volume commitment.
Victor Sage
Victor Sage
30 Oct 2026
Ocean Sciences has committed A$100,000 to a 12-month research program testing whether Sargassum-derived alginate can recover gold, silver and potentially rare earth elements from retired data centre hardware. The project gives the seaweed company a new industrial angle, but remains firmly at the laboratory stage.
Victor Sage
Victor Sage
28 Oct 2026
SCX.ai has reported positive operating cash flow in its first quarter as an ASX-listed company, alongside a 54% increase in annualised recurring revenue since its prospectus. The sovereign AI infrastructure provider also has more than 100 commercial customers and $23.9 million in cash, but its next test is converting new capacity and partnerships into durable revenue.
Sophie Babbage
Sophie Babbage
27 Oct 2026
Janus Electric has signed a non-binding MOU with ConGlobal for a proposed 20-truck Class 8 conversion pilot in Texas. A successful pilot could open a pathway to conversion, battery-swapping and servicing operations across ConGlobal’s 31 US depots, although no binding orders or commercial terms have been agreed.
Victor Sage
Victor Sage
26 Oct 2026
Algorae has secured exclusive Australian commercial rights across eight Umedica-branded molecules while separately advancing a Umedica-supplied product towards regulatory approval. The broader arrangement remains partly non-binding, with financial terms undisclosed and TGA approval still pending.
Victor Sage
Victor Sage
19 Oct 2026
Talius Group returned to positive operating cash flow in the September quarter as revenue, subscriptions and annualised recurring revenue all increased. The next test is converting newly contracted work into active deployments, recurring revenue and cash receipts.
Victor Sage
Victor Sage
15 Oct 2026
Optiscan Imaging has lodged a US FDA 510(k) application for InVue, its precision surgery device designed to provide cellular-level imaging during operations. The submission moves the technology into formal regulatory review, but clearance and commercialisation remain uncertain.
Victor Sage
Victor Sage
5 Oct 2026
Optiscan Imaging has lodged a 510(k) submission for its InForm digital pathology device, moving the product from development into formal US regulatory assessment. FDA clearance is not assured, but a successful determination could open the door to commercial distribution in the company’s target market.
Victor Sage
Victor Sage
1 Oct 2026
H3 Energy has consolidated ownership of its Alinya hydrogen and helium project and reframed Warro as a potential commercial gas development, but its annual report warns that funding remains critical. The company ended FY2026 with A$900,434 in cash, net liabilities of A$551,671 and a material uncertainty over its ability to continue as a going concern.
Maxwell Dee
Maxwell Dee
30 Sept 2026

Browse the archive

Full archive